<DOC>
	<DOCNO>NCT01290302</DOCNO>
	<brief_summary>The purpose study assess bioequivalence subcutaneous Vidaza® subcutaneous Luitpold Azacitidine pharmacokinetics assess comparative safety subcutaneous Vidaza® versus subcutaneous Luitpold Azacitidine .</brief_summary>
	<brief_title>Bioequivalence Trial Luitpold Azacitidine Versus Vidaza® Patients With Myelodysplastic Syndrome , Myelofibrosis , Chronic Myeloid Leukemia Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>To assess bioequivalence Vidaza® Luitpold Azacitidine pharmacokinetics , term Cmax , AUC0-t AUC0-∞ , follow SC administration . To assess comparative safety Vidaza® versus Luitpold Azacitidine 2 day study period .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Signed informed consent obtain prior initiation studyspecific procedure . Patients one follow myelodysplastic syndrome follow FrenchAmerican British ( FAB ) subtypes : refractory anemia ( RA ) , RA ring sideroblast ( accompany neutropenia , thrombocytopenia , require transfusion ) , RA excess blast ( RAEB ) , RAEB transformation ( RAEBT ) , chronic myelomonocytic leukemia ( CMMoL ) ; myelofibrosis ; chronic myeloid leukemia ; chronic lymphocytic leukemia 's physician feel receive azacitidine . Male female patient age least 18 year . ECOG Performance Status 02 . Life expectancy &gt; = 3 month . Adequate organ function , include follow : Hepatic Total bilirubin &lt; = 1.5 x upper limit normal ( ULN ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; = 2 x ULN Renal Serum creatinine &lt; = 1.5 x ULN . Female patient childbearing potential must negative pregnancy test must use least one form contraception approve Investigator 4 week prior study 4 month last dose azacitidine . Male patient must use form barrier contraception approve investigator study 4 month last dose azacitidine . Hypersensitivity azacitidine mannitol . Anticipated need RBC platelet transfusion 2 day prior 2 day treatment initiation . Chemotherapy ( exclude previous azacitidine treatment ) radiotherapy within 4 week randomization ( 6 week nitrosoureas mitomycin C ) . Significant electrophysical abnormality pretrial EKG . Present history locally advance metastatic malignant disease leukemia . Use recreational drug history drug addiction , within prior 6 month . Known history positive hepatitis screen , include hepatitis B surface antigens HCV antibody . Known history HIV syphilis . History clinically significant adverse event due chemotherapy , radiotherapy investigational agent . Presence advance malignant hepatic tumor . Presence ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia , uncontrolled thrombotic hemorrhagic disorder , serious uncontrolled medical disorder . Presence significant central nervous system psychiatric disorder ( ) would hamper patient compliance . Treatment investigational agent , participation another clinical trial within 28 day prior study entry . Pregnant breastfeeding patient patient childbearing potential use adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>